Personalized mRNA Vaccine Shows Sustained Benefit in Melanoma Patients After Five Years
Similar Articles
Pre-Surgery Immunotherapy Shows Promise for a Subtype of Colorectal Cancer
Immunotherapy Shows Promise as Pre-Surgery Treatment for Specific Bowel Cancer
Pancreatic Cancer Survival Advances Through New Drugs and Vaccines
Gleevec, a Cancer Drug Developed Through Clinical Trials, Continues to Save Lives Decades After Approval
Scientists Develop Drug Method to Boost Natural Killer Cells Against Multiple Cancers
A personalized mRNA vaccine, used in combination with the immunotherapy drug Keytruda, has shown a significant and sustained reduction in cancer recurrence and improved survival for patients with high-risk melanoma. The five-year results from a clinical trial show a 49% reduction in the risk of recurrence or death compared to using Keytruda alone. The treatment's developers are now preparing to seek FDA approval based on the results of a larger, ongoing Phase 3 trial.
Facts First
- A 49% reduction in risk of recurrence or death for patients receiving a personalized mRNA vaccine plus Keytruda, compared to Keytruda alone.
- 68.8% of combination therapy patients remained cancer-free after five years, versus 49.1% of patients on Keytruda alone.
- 92% of combination therapy patients were alive at the five-year mark, compared to 71% of those on Keytruda alone.
- The vaccine is custom-made by sequencing a patient's tumor to target unique molecular fingerprints called neoantigens.
- A Phase 3 trial with nearly 1,000 patients is currently underway, with the goal of seeking FDA approval.
What Happened
A five-year follow-up of a clinical trial has shown that a personalized messenger RNA (mRNA) vaccine, called intismeran, combined with the immunotherapy drug Keytruda (pembrolizumab), significantly improves outcomes for patients with high-risk melanoma. The trial involved 157 patients in Australia and the U.S. who had undergone surgery to remove their tumors. The results, published in the Journal of Clinical Oncology and presented at the American Society of Clinical Oncology conference, show that 68.8% of patients receiving the combination therapy remained cancer-free, compared to 49.1% of patients receiving Keytruda alone. At the five-year mark, 92% of patients who received the combination therapy were alive, compared to 71% of those who used Keytruda alone.
Why this Matters to You
If you or a loved one is diagnosed with a high-risk form of melanoma, this development may offer a more effective treatment option to prevent the cancer from returning after surgery. The combination therapy appears to provide a substantial, long-term survival benefit. The side effects reported in the trial were mild, including chills and minor pain at the injection site, which suggests the treatment could be well-tolerated. For the broader public, this represents a major advance in personalized cancer medicine, demonstrating that vaccines tailored to an individual's specific tumor can train the immune system to fight cancer more effectively.
What's Next
Moderna, which developed the intismeran vaccine, and Merck, the manufacturer of Keytruda, are collaborating on a Phase 3 trial involving nearly 1,000 patients, which is currently underway. The goal following the analysis of Phase 3 results in the coming months is to seek FDA approval. If successful, this could make the personalized vaccine combination a new standard of care for patients with high-risk melanoma.